TYRA Biosciences

EMC-IRB-25-039

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of dabogratinib (TYRA-300) in Participants with EGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer